3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors

Bioorg Med Chem Lett. 2009 May 1;19(9):2464-7. doi: 10.1016/j.bmcl.2009.03.054. Epub 2009 Mar 18.

Abstract

A series of 3-(arylamino)-3-phenylpropan-2-olamines was prepared and screened for their ability to inhibit monoamine reuptake. A number of analogues displayed significant dual norepinephrine and serotonin reuptake inhibition. Compounds in this class exhibited minimal affinity for the dopamine transporter.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology
  • Animals
  • Chemistry, Pharmaceutical / methods*
  • Dogs
  • Dopamine Plasma Membrane Transport Proteins / antagonists & inhibitors*
  • Dopamine Plasma Membrane Transport Proteins / chemistry
  • Drug Design
  • Humans
  • Inhibitory Concentration 50
  • Ligands
  • Models, Chemical
  • Norepinephrine / antagonists & inhibitors*
  • Propanolamines / chemical synthesis*
  • Propanolamines / pharmacology
  • Selective Serotonin Reuptake Inhibitors / chemical synthesis*
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Structure-Activity Relationship

Substances

  • Adrenergic Uptake Inhibitors
  • Dopamine Plasma Membrane Transport Proteins
  • Ligands
  • Propanolamines
  • Serotonin Uptake Inhibitors
  • Norepinephrine